Hiroshi Mori
Kanazawa, 9208641, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
High-dose ¹³¹I-metaiodobenzylguanidine therapy in relapsed high-risk neuroblastoma: a descriptive analysis of clinical outcomes and associated factors.
Journal: European journal of nuclear medicine and molecular imaging
Published: August 27, 2025
Dynamic expression of the myocardial sigma-1 receptor after doxorubicin cardiomyopathy using radioiodine-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5 V) imaging.
Journal: Annals of nuclear medicine
Published: April 01, 2025
Positive Protective Effects of Sigma-1 Receptor Stimulation with Fluvoxamine after Myocardial Ischemia and Reperfusion in Rats.
Journal: Molecular imaging and biology
Published: January 09, 2025
Publisher Correction: Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma.
Journal: Scientific reports
Published: August 06, 2024
Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma.
Journal: Scientific reports
Published: January 24, 2024
Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac 123I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT.
Journal: Annals of nuclear cardiology
Published: May 31, 2023
Radiation exposure lymphocyte damage assessed by γ-H2AX level using flow cytometry.
Journal: Scientific reports
Published: May 09, 2023
Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan.
Journal: Endocrine journal
Published: December 25, 2022
125I-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (125I-OI5V) imaging visualized augmented sigma-1 receptor expression according to the severity of myocardial ischemia.
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: April 12, 2022
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.
Journal: Annals of nuclear medicine
Published: September 20, 2021
Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy.
Journal: Annals of nuclear medicine
Published: August 11, 2021
Last Updated: 09/26/2026